Monoclonal Antibodies for the Treatment of Nasal Polyps.

Abstract

Biologics are novel therapeutic medications developed for the targeted therapy for a variety of inflammatory conditions. The biologics currently investigated for the treatment of chronic rhinosinusitis (CRS) with nasal polyps modulate specific inflammatory pathways involved in the pathogenesis of disease. Investigations have focused on the most severe form of the disease, namely, CRS with nasal polyps. It is hoped that specific targeted therapies using these biologics can significantly modulate the immune system, offering both disease control and symptomatic relief. This review summarizes those therapies that have been used to treat nasal polyps.

• Authors: Thomas J Willson, Robert M Naclerio, Stella E Lee
• Journal: Immunology and allergy clinics of North America (Immunol Allergy Clin North Am) Vol. 37 Issue 2 Pg. 357-367 (05 2017) ISSN: 1557-8607 [Electronic] United States
• PMID: 28366482 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2017 Elsevier Inc. All rights reserved.

Chemical References

• Antibodies, Anti-Idiotypic
• Antibodies, Monoclonal
• Biomarkers
• Interleukin-13
• Interleukin-5
• Sialic Acid Binding Immunoglobulin-like Lectins
• anti-IgE antibodies
• Interleukin-4

Topics

• Antibodies, Anti-Idiotypic (pharmacology, therapeutic use)
• Antibodies, Monoclonal (pharmacology, therapeutic use)
• Biomarkers
• Chronic Disease
• Humans
• Immunomodulation (drug effects)
• Interleukin-13 (metabolism)
• Interleukin-4 (metabolism)
• Interleukin-5 (antagonists & inhibitors, metabolism)
• Molecular Targeted Therapy
• Nasal Polyps (drug therapy, etiology, metabolism)
• Rhinitis (complications, drug therapy, immunology, metabolism)
• Sialic Acid Binding Immunoglobulin-like Lectins (pharmacology, therapeutic use)
• Signal Transduction (drug effects)
• Sinusitis (complications, drug therapy, immunology, metabolism)